Skip to main content

Table 2 Multivariable logistic regression analyses predicting PrEP experience

From: Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians

  ALL GENDERSa
N = 140/1405
FEMALEb
n = 24/379
MALEc
n = 111/1009
  N (%) AOR (95% CI) p-value N (%) AOR (95% CI) p-value N (%) AOR (95% CI) p-value
Gender
 Female 24 (6.3) 1       
 Male 111 (11.0) 1.5 0.9–2.6 0.088     
 Transgender 5 (29.4) 3.4 1.0–11.4 0.049     
Age (years)
 < 30 12 (16.7) 2.1 1.1–4.2 0.031      9 (20.0) 2.3 1.0–5.0 0.048
 30–40 33 (12.3) 1.6 1.0–2.5 0.034      25 (14.1) 1.8 1.1–3.0 0.026
 > 40 95 (8.9) 1        77 (9.8) 1   
Enrolling centre
 General hospital 32 (7.3) 1    3 (2.5) 1       
 Research Institute 57 (13.5) 1.9 1.2–3.1 0.006 12 (11.2) 5.5 1.4–21.6 0.014     
 University Institute 51 (9.4) 1.3 0.8–2.1 0.244 9 (5.9) 2.3 0.6–9.1 0.250     
Member of HIV associations
 Yes 42 (17.5) 2.2 1.5–3.3 <0.001 6 (10.3) 2.6 0.9–7.6 0.074 33 (18.9) 2.2 1.4–3.4 0.001
Route of HIV transmission
 Heterosexual intercourse 27 (5.7) 1        16 (6.5) 1   
 Homo/Bisexual intercourse 57 (12.2) 1.7 1.0–2.8 0.061      49 (11.4) 1.6 0.9–3.0 0.109
 Intravenous Drug Use 34 (14.8) 2.6 1.5–4.5 0.001      29 (17.0) 3.1 1.6–5.9 0.001
 Other/unknown 22 (9.2) 1.5 0.8–2.8 0.172      17 (10.4) 1.7 0.8–3.5 0.151
Change ART (last 12 months)
 Yes          32 (14.5) 1.5 0.9–2.3 0.102
Undetectable HIV RNA
 No 39 (13.7) 1.6 1.1–2.5 0.018 10 (14.5) 4.5 1.8–11.3 0.002     
Partners’ number (last 3 months)
 No partner 36 (8.1)     7 (4.6) 1       
 Single partner 70 (9.5)     13 (6.0) 1.5 0.6–4.0 0.421     
 Multiple partners 34 (15.0)     4 (36.4) 17.5 3.6–84.9 <0.001     
  1. AOR adjusted odds ratio, CI Confidence Interval, ART antiretroviral therapy, STI sexually transmitted infection
  2. aIncluding Transgender persons (n = 5/17). Significant variables at univariate analysis (p < 0.100): Gender; Age; Enrolling centre; Member of HIV associations; Route of HIV transmission; Undetectable HIV RNA; Partners’ number (last 3 months)
  3. bSignificant variables at univariate analysis (p < 0.100): Age (forced variable); Enrolling centre; Member of HIV associations; Route of HIV transmission; Undetectable HIV RNA; CD4 count/mm3; STI (last 12 mos); Partners’ number (last 3 months)
  4. cSignificant variables at univariate analysis (p < 0.100): Age; Enrolling centre; Member of HIV associations; Route of HIV transmission; Change ART (last 12 months)